Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Kyverna begins rolling submission for autoimmune CAR-T as FDA requests more natural history analysis
(6h)
FDA Commissioner Marty Makary to resign, capping turbulent tenure: report
(9h)
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
(11h)
Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
(12h)
AstraZeneca’s $800M bet undermined by immunogenicity in phase 3
(13h)
Charles River debuts AI diagnostic tool to cut down pathology timelines
(14h)
Bayer scraps protein therapy for hypertension from phase 1, along with neuropathic pain drug
(17h)
Roche nabs European approval for second Eli Lilly-partnered Alzheimer’s test
(18h)
Blood-based approach could detect early heart, kidney disease, study finds
(20h)
Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed
(21h)
BioPharma Dive
FDA chief Marty Makary resigns from agency, ending tumultuous tenure
(8h)
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
(10h)
Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
(14h)
A year after Vertex’s big launch, pain drug research faces a pivotal moment
(15h)
GSK cuts deal with Sino to broaden reach of hepatitis B drug
(1d)
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
(1d)
Biotech layoffs are easing, but is the worst over?
(1d)
The capacity crunch in biopharma is a location problem
(1d)
Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies
(1d)
Lilly to invest extra $4.5B across Indiana manufacturing
(4d)
Endpoints News
Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
(4h)
EU reaches provisional deal on Critical Medicines Act
(9h)
FDA Commissioner Makary to resign, source says
(9h)
Iran war disruptions begin to emerge upstream of the pharma supply chain
(9h)
What I learned at a journalism fellowship about covering healthcare AI
(10h)
Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
(11h)
Pfizer and Arvinas give disappointing breast cancer drug to Rigel
(11h)
Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
(12h)
Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
(13h)
Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AI
(13h)
BioSpace
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge
(13h)
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
(14h)
BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival
(15h)
FDA turns to old drugs to address new diseases, persistent medical needs
(15h)
Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls
(1d)
Makary’s reported FDA removal could be 'broad positive' for biopharma
(1d)
Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher
(1d)
Advances in RSV Vaccine Research and Development
(1d)
Merck, Amgen double down on bad cholesterol to vanquish number 1 killer
(2d)
Published FDA rejections point to manufacturing, data gaps as key stumbling blocks
(2d)
STAT News
Why Marty Makary was the worst FDA commissioner in 25 years
(6h)
Males who discuss suicide seek help less often than females, report finds
(7h)
European Union inks a draft deal to boost local production of medicines and avoid shortages
(8h)
Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
(9h)
Supreme Court extends mifepristone deadline
(10h)
Hims takes a $33 million hit from GLP-1 ‘pivot’
(10h)
Hims’ sales miss as telehealth competition grows
(10h)
STAT examines America’s deadliest drug
(12h)
We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
(13h)
Capsida says it still doesn’t know what caused gene therapy death
(14h)
BioPharma Trend
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1d)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(4w)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(1mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(1mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(1mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(1mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(1mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(1mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(1mo)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(1mo)
Drug Channels
340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)
(16h)
The Hidden Costs of Over-Customizing Your Hub Technology Stack
(4d)
Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point
(1w)
Where Gross-to-net Pressure Actually Lives After Launch
(2w)
Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, and a Peek Behind the Scenes at DCI
(2w)
Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels
(3w)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care
(3w)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground
(3w)
The Omnichannel Gap: Building the CRM of the Future for Patient Services
(3w)
The Hidden Pitfalls of Hub Transitions—and How to Navigate Them
(4w)
European Biotechnology Magazine
Infex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead asset
(15h)
EktaH links novel obesity drug to fat loss, muscle retention in early-phase trial
(18h)
Tolemy Bio raises €1.4m to build AI control panel for cell biology
(19h)
The DASbox® Mini Bioreactor System: Small scale. Big results
(2d)
Angelini inks $4.1B Catalyst takeover to fuel US expansion
(5d)
InflaRx attracts strong investor interest with US share offering turning to kidney
(5d)
Scarlet raises £3.2 million to advance lab-grown red blood cell therapies
(5d)
For several billions: Bayer adds Perfuse Therapeutics to portfolio of eye therapies
(6d)
Switzerland’s biotech sector defies tough markets with record revenue
(6d)
Macrocycles: big is the new beautiful
(6d)
Drug Hunter
From Patient to Target: The Discovery of GDF15 in Hyperemesis Gravidarum
(11h)
Endometriosis Inspires Re-Examination of Known Targets at the Inaugural HERS Meeting
(1d)
Module 4, Section 3: Breakdown of Binding
(1d)
etripamil
(4d)
atirmociclib
(5d)
Metabolic Stability in Peptide Therapeutics
(6d)
EPSA: A Useful Metric Across Chemical Space
(6d)
infigratinib
(1w)
IAM1363
(1w)
Module 4, Section 2: All About Assays
(1w)
Labiotech.EU
Biotech risk management: The hidden risks behind layoffs
(13h)
The real reason CGT programs struggle to scale
(18h)
Inside CSL’s strategy to simplify a biotech giant
(1d)
The biggest biotech funding rounds in April 2026
(4d)
The rise of trispecific antibodies: Biopharma’s next big bet after bispecifics
(5d)
Making labs smarter for scientific breakthroughs
(5d)
Top biotech deals in April 2026
(6d)
Sickle cell disease after Casgevy: seven companies to watch in 2026
(6d)
Needle-free diabetes care: 6 devices that painlessly monitor blood sugar
(1w)
Five companies pushing biotech in Scotland
(2w)
Bio IT World
AI Framework for Differentiating Neurodegenerative Diseases
(21h)
Trends from the Trenches: The Capability Jump of AI and Its Impact
(5d)
Bacteria: Unsung Players in the Tumor Microbiome
(6d)
Much Progress Needed Planning Research to Consider Sex as a Biological Variable
(1w)
Craig Venter, Genomics Pioneer and Visionary, Dies
(2w)
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
(2w)
Bio-IT World Honors Four 2026 Innovative Practices Winning Projects
(2w)
Cepheid, Oxford Nanopore Expand Partnership, Revvity Launches New Platform, More
(2w)
fMRI-Based Mega-Study of Psychedelics Reveals Patterns of Brain Signaling Reorganization
(3w)
From Brain Implant to Lifelong Companion: Michel Maharbiz Unveils Epia Neuro
(3w)
GEN News
10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit
(58m)
AAVs in Focus: Practical Approaches to Capsid Analytics and Plasmid DNA Control
(6h)
Brain Histamine Map Links Genetic Factors to Mental Health and Psychiatric Disorders
(7h)
Acute Myeloid Leukemia Therapy Improved by CRISPR Stem Cell Transplant
(7h)
Stable Producer Cell Line Generation Platform Adds to VIVEbiotech’s Lentiviral Vector Manufacturing Capabilities
(1d)
Cholesterol Drug May Weaken Ovarian Cancer’s Metastatic Defense
(1d)
How HIV-1 Develops Resistance to Broadly Neutralizing Antibodies
(1d)
Genewiz Launches Gene Synthesis 2.0
(1d)
RegVelo AI Model Predicts Cell Fate, Tackles Developmental Disorders and Cancer
(1d)
StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy
(2d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(1mo)
Understanding High-Risk Essential Thrombocythemia
(1mo)
Son’s Decision to Donate Gave His Father a Second Chance
(1mo)
Functional Precision Medicine Advances Brain Tumor Care
(1mo)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(1mo)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(1mo)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(1mo)
How Honest Conversations Strengthened a Couple After Cancer
(1mo)
Cardiac Health in Cancer Survivors: A Growing Need
(1mo)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(1mo)
Contract Pharma
AOP Health, VRG Therapeutics Unite to Advance Inflammation and Immunology Target
(6h)
Ribo, Insilico Medicine to Partner on AI-Driven siRNA Drug Development
(8h)
Lonza Launches Xcite AAV Producer Cell Line Platform
(11h)
Boehringer Ingelheim Advances Partnership with Brainomix to Improve Pulmonary Fibrosis Care
(11h)
Quantitative Biosciences Institute Taps Dr. John Young as Chief Strategy Officer
(12h)
BMS, Hengrui Pharma Partner to Advance Early Stage Programs
(13h)
Aldevron, Minaris Renew Lentiviral Plasmid Agreement
(13h)
Colbert Packaging Unveils New Vision Inspection Hardware and Software
(1d)
Cellares, ProTgen to Automate Manufacturing of Novel Progenitor T-Cell Therapy
(1d)
Avid Bioservices Appoints Kerri McCullough Wood as Chief Commercial Officer
(1d)
Pharma Times
Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
(16h)
SMC backs first-line metastatic bladder cancer combination after trial results
(17h)
Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
(1d)
Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
(1d)
UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
(5d)
Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
(5d)
Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
(1w)
MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
(1w)
Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
(2w)
Subcutaneous pembrolizumab begins rollout across NHS hospitals
(2w)
Medcity News
How Healthcare Leaders are Reacting to the White House’s Proposed Fertility Benefit Rule
(4h)
Inviting Investors and Corporate Business Development Leaders to Bullseye
(7h)
Sanford Health Continues M&A Push with North Memorial Health Deal
(7h)
Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B
(8h)
Five Ways Technology Can Transform Chronic Care Management
(12h)
AI in Transplant Diagnostics: Turning Complexity into Clinical Clarity
(13h)
Digital Fatigue: Healthcare’s Next Patient Experience Crisis
(13h)
How User-Generated Content is Transforming Pharma Insights on the Patient Experience
(15h)
About 67% of Employers Cover GLP-1s for Weight Management; That Could Decline in 2027
(1d)
How Beth Israel Lahey Health Cut Fax Failures From 34% to 4% — and Saved $4 Million
(1d)
Chemical & Engineering News
Marty Makary leaves a mixed legacy as FDA commissioner
(3h)
Helium supplies are tight—and it could get worse
(5h)
Business Watch: Massive complex planned for Abu Dhabi; Angelini to buy Catalyst for $4.1 billion
(6h)
Advances in imaging tools offer spatial biology for the AI age
(6h)
How a Canvas hack forced chemists to communicate creatively
(8h)
How cosmic dust forms from atoms in space
(10h)
Obituary: John Firkins
(14h)
Obituary: Charles T. Buse
(14h)
Letters to the editor on scientific sleuthing and lab safety
(1d)
Discarded jellyfish could be a sustainable collagen source
(1d)
The Pharma Letter
Hengrui Pharma strikes $15.2 billion asset deal with BMS
(11h)
Strong start to 2026 for Lundbeck, with 21% revenue growth
(12h)
Bayer beats estimates to send shares higher
(12h)
FDA acts to make most of drug repurposing opportunities
(13h)
Cellular Intelligence acquires Novo Nordisk's cell therapy program for Parkinson's
(13h)
GSK inks hepatitis B collaboration with Sino Bio
(13h)
Higher dose Wegovy demonstrates nearly 28% weight loss
(15h)
DNA synthesis market forecast to top $30 billion by 2035
(15h)
Early data revive interest in OX40 immunotherapy
(16h)
Erasca partners with Merck on best-in-class pan-RAS molecular glue
(16h)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(1mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(1mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(1mo)
Treating Triple Negative Breast Cancer in the Frontline Setting
(1mo)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(1mo)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(1mo)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(1mo)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(1mo)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(1mo)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(1mo)
MedWatch
Analyst expects strong Vimkunya results after Bavarian's raised forecast
(13h)
WS Audiology puts faith in own brands despite Italian-Danish megadeal
(14h)
WS Audiology lags behind in key business area and goes all in on next wave of products
(14h)
Coloplast CFO on major write-down: "We've never seen anything like this"
(15h)
Lundbeck raises its full-year guidance
(15h)
Positive momentum for Bavarian, but double-digit jump unlikely, says analyst
(16h)
Hims & Hers plummets on weak earnings guidance
(17h)
US company gets the green light in Europe to conduct trials of GLP-1 gene therapy for type 2 diabetes
(17h)
Coloplast maintains reduced outlook for the year
(18h)
Novo's high-dose Wegovy shows greater efficacy
(19h)
In The Pipeline
More Vague, But More Useful
(4h)
Those Pesky Post Translational Modifications
(1d)
The Latest News in Vaccine Obstruction
(5d)
Ubiquitin Rides Again
(1w)
Helium and the Strait of Hormuz
(1w)
An Open Letter to Jay Bhattacharya
(2w)
The FDA Cracks Down on Tavneos
(2w)
The Latest Synthetic Automation Proposal
(2w)
No Heart Cancer? There's a Reason
(2w)
Fluorines As Reactive Handles, Eh?
(3w)
Pharmaphorum
Reports: Makary out, Diamantas in as FDA commissioner
(8h)
Isomorphic raises $2.1bn for AI drug hunt
(11h)
Boehringer, Brainomix plan new trial of lung fibrosis AI
(13h)
EU agrees plan to tackle essential medicine shortages
(14h)
Novo says high-dose Wegovy can cause 28% weight loss
(15h)
BMS signs $15.2bn R&D alliance with China's Hengrui
(17h)
Cellular Intelligence scoops up Novo's Parkinson's therapy
(18h)
Novo Nordisk microRNA drug fluffs its lines in heart failure
(1d)
GSK taps enlists local aid for Chinese rollout of hep B drug
(1d)
GSK enlists local aid for Chinese rollout of hep B drug
(1d)
Drug Discovery Weekly
Introducing Benchling Biologics: AI infrastructure for modern drug discovery (Americas Session)
(13h)
Introducing Benchling Biologics: AI infrastructure for modern drug discovery (Europe Session)
(13h)
How strong is the UK’s advanced therapy sector?
(13h)
Therapy for X-CGD shows early promise, Ensoma reports
(13h)
DDW Highlights: 12 May 2026
(15h)
University of Sheffield wins global prize for ALS project
(15h)
First GLP-1 gene therapy gets green light for diabetes trial
(16h)
CellCentric raises $220m to advance trials of oral myeloma drug
(17h)
Cyclic peptide drug design: From experimental discovery to AI-driven computation
(18h)
Congress extends Rare Pediatric Disease Priority Review Voucher programme through 2029
(1d)
HIT Consultant
Included Health Launches Provider Connect AI Assistant for High-Quality Physician Matching
(10h)
Labcorp Integrates Full Diagnostic Menu into Epic Aura: Streamlining Lab Workflows for U.S. Health Systems
(11h)
Medbridge Launches Outcomes Offering: Connecting Patient Care to Clinical Efficacy and Payment
(13h)
Evolution Devices Announces First Multi-Site Clinical Sale of EvoWalk to Sheltering Arms Institute
(13h)
1upHealth Deploys All CMS-0057-F Interoperability and Prior Authorization APIs Ahead of 2027 Deadline
(13h)
The $262B “Acceptance”: Why It’s Time to Stop Treating Denials as an Unavoidable Cost
(21h)
Basata Secures $21M to Rebuild Healthcare’s Operational Layer: Automating Referrals and Scheduling End-to-End
(1d)
Transforming Medical Coding Operations Through Hybrid Intelligence Design
(1d)
How Lucent and Tempus Are Using AI to Spot Alzheimer’s Earlier
(2d)
Withings Report Reveals Why Menopause is a Critical Cardiovascular Window
(4d)
Insights: Pink Sheet
White House MFN Push In Foreign Markets Could Backfire On US, Limit Access
(3h)
US FDA OTP Chief Says Cell And Gene Therapy CMC Readiness Remains Key Roadblock
(6h)
Germany Aims To Link Drug Rebates To Local R&D Activity
(7h)
Makary Goes: Embattled US FDA Commissioner Resigns Amid White House, Special Interest Anger
(8h)
EU Joint Clinical Assessments: Could Zepzleca, Imdylltra or Itvisma Be Next?
(11h)
US Supreme Court Extends Hold On Mifepristone In-Person Dispensing Ruling, Concerns Remain
(1d)
Stay Or Go? US FDA World Awaits Makary’s Fate, Agency Business Continues
(1d)
First-In-China Trials May Be ‘Counterproductive’ For Sponsors, US FDA CBER Official Says
(1d)
After Leucovorin Success, US FDA Eyes More Drug Repurposing
(1d)
EU Set To Introduce AMR Vouchers & Regulatory Sandboxes This Year
(1d)
BioXconomy
Compliance updates—False Claims Act, MFN, FDA clinical trial results and 340B
(5h)
Executive appointments in biopharma legal roles
(7h)
DOJ declares ‘war on fraud’ on pharma as enforcement priorities shift
(12h)
Parexel buys pharmacovigilance tech firm Vitrana in latest AI-focused deal
(12h)
Eyes on Asia: BeOne Medicines, Takeda, GSK
(16h)
Rosalind Davis talks pharma pricing shifts with new laws, other impacts
(16h)
Gen Z's AI paradox: Why the most tech-savvy generation trusts healthcare AI the least
(17h)
CEPI’s Pandemic Preparedness engine uses AI to predict the next outbreak
(1d)
CEPI’s Pandemic Preparedness engine uses AI to predict the next outbreak
(1d)
Columna Capital acquires Evidenze Group to expand CRO services across Europe
(1d)
BioCentury
Solving AAV’s one-and-done problem: ASGCT highlights
(1d)
Thin ice for Makary, redosing AAVs — a BioCentury podcast
(1d)
GSK takes rights to cardiovascular program from China-based SiranBio: Deals Report
(1d)
Entrada, enGene lose over half their value on clinical readouts
(1d)
Makary’s grip slips at FDA, triggering speculation on successor
(4d)
Odyssey completes journey to NASDAQ: Public Equity Report
(4d)
Tr1X: Inducing long-term immune tolerance with allogeneic Tr1 cells
(4d)
Enodia: Degrading secreted proteins before maturation
(4d)
Two mechanisms vie to deliver first hypoxic ischemic encephalopathy drug
(5d)
Mounjaro overtakes Keytruda for the first time
(5d)
SCRIP
Makary’s Exit Resurrects Questions About US FDA’s Direction Under Trump Administration
(2h)
Alkermes Sees Upside To Its Avadel Buy With Phase III Lumryz Win In IH
(4h)
Rigel Will Take Over Pfizer/Arvinas’s Recently Approved Veppanu
(5h)
Where No One Has Gone Before: Enterprise Targets ENaC Success With ETD001
(6h)
Scrip Awards Podcast: Call For Entries 2026, New AI Category, Triana Interview
(11h)
Bayer Back In The Market For Bolt-Ons
(12h)
Stock Watch: US Pharma Rescues Earnings Season As Lilly, AbbVie And BMS Beat
(16h)
Hengrui, BMS Strike Huge $15.2bn Alliance For Bundle Of Preclinical Assets
(17h)
Bridging The Reimbursement And Screening Gap: AstraZeneca’s Asia Strategy
(17h)
Hengrui/Braveheart’s Myosin Inhibitor Shows nHCM Disease-Modifying Signal
(18h)